<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

LSX: THE COMMUNITY FOR LIFE SCIENCE EXECUTIVES

LSX, formerly Biotech and Money, is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses. We achieve this through a programme of high-level conferences and networking events, via content that showcases and shares the expertise of investors, senior leaders and industry stakeholders, as well as through bespoke initiatives.

Upcoming Events
Blog and Content
Our Community

OUR CONFERENCE AND COMMUNITY BRANDS

LSX World Congress.png
Investival Header.png
LSX Nordic Congress-1.png
LSX World Congress USA
LSX CEO Forum
LSX Connect
LSX Investor Club

INVESTMENT AND IPOS

Lifestars Awards 2018 celebrate life science successes

LSX (formerly Biotech and Money) hosted the Lifestars Awards at the Honoura...

Read More

€79m Series C pushes Galecto Biotech’s pipeline into next phase of clinical development

Key learnings: Ysios Capital and OrbiMed led Galecto Biotech’s €79 million ...

Read More

Driving developments to defeat ageing: Q&A with Aubrey de Grey

In February 2019, key stakeholders in the growing longevity industry will c...

Read More
View More

M&A AND DEAL MAKING

Medius Deal Watch: September-October 2018

There was much speculation last year that the US tax cuts that favoured the...

Read More

Lifestars Awards 2018 celebrate life science successes

LSX (formerly Biotech and Money) hosted the Lifestars Awards at the Honoura...

Read More

M&A deals and the pharmaceutical sector: Are your IP ducks in a row?

2018 has so far been a productive year for M&A deals in the pharmaceutical ...

Read More
View More

R&D TO COMMERCIALISATION

Lifestars Awards 2018 celebrate life science successes

LSX (formerly Biotech and Money) hosted the Lifestars Awards at the Honoura...

Read More

€79m Series C pushes Galecto Biotech’s pipeline into next phase of clinical development

Key learnings: Ysios Capital and OrbiMed led Galecto Biotech’s €79 million ...

Read More

Driving developments to defeat ageing: Q&A with Aubrey de Grey

In February 2019, key stakeholders in the growing longevity industry will c...

Read More
View More

IP, REGULATION AND COMPLIANCE

AI update: medical software and pre-emption

In light of the rapidly expanding field of medical software technology, and...

Read More

Artificial intelligence and machine learning in healthcare: An intellectual property perspective

Artificial intelligence (AI), particularly machine learning (ML), is alread...

Read More

Addressing emerging themes in life science IP

Marks & Clerk’s intellectual property (IP) summit in Cambridge on 16 Octobe...

Read More
View More

TALENT AND EXECUTIVE STRATEGY

Lifestars Awards 2018 celebrate life science successes

LSX (formerly Biotech and Money) hosted the Lifestars Awards at the Honoura...

Read More

Bolstering women in the C-suite and boardroom

The leadership landscape within life sciences is beginning to change. More ...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More
View More

COMMUNITY PARTNERS AND PREMIUM COMMUNITY MEMBERS

Alacrita
allen and overy
Appleyard Lees
barclays
Cancer Research UK.jpg
CMS Cameron Mckenna.png
Covington 300x200.jpg
Dyadic.png
gje.png
Gallagher.png
Horizon Logo.png
illumina-logo.svg
Inceptua
Marks & Clerk Intellectual Property Services.jpeg
Storm Therapeutics.png
Xplico.png